Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

   Terminated · Phase 2 · Schizophrenia

   NCT05443724 · AbbVie Inc. · 61 U.S. investigators

   $4.7Mresearch payments

2. Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

   Terminated · Phase 3 · RSV Immunisation

   NCT06252285 · Sanofi Pasteur Inc. · 68 U.S. investigators

   $4.6Mresearch payments

3. ACP-204 in Adults With Alzheimer's Disease Psychosis

   Recruiting · Phase 2, Phase 3 · Alzheimer's Disease Psychosis

   NCT06159673 · Acadia Pharmaceuticals Inc · 38 U.S. investigators

   $4.6Mresearch payments

4. A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

   Active, not recruiting · Phase 2 · Coeliac Disease

   NCT06557772 · Sanofi US Services Inc. · 39 U.S. investigators

   $4.6Mresearch payments

5. A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

   Recruiting · Phase 3 · Psychosis Associated With Alzheimer's Disease

   NCT06126224 · E.r. Squibb & Sons, L.l.c. · 54 U.S. investigators

   $4.6Mresearch payments

6. Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

   Completed · Phase 3 · Idiopathic Pulmonary Fibrosis

   NCT04708782 · United Therapeutics Corporation · 93 U.S. investigators

   $4.5Mresearch payments

7. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

   Active, not recruiting · Phase 3 · Systemic Lupus Erythematosus

   NCT05843643 · AbbVie Inc. · 125 U.S. investigators

   $4.5Mresearch payments

8. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   Active, not recruiting · Phase 1 · Pancreatic Ductal Adenocarcinoma

   NCT06586515 · Eli Lilly and Company · 25 U.S. investigators

   $4.4Mresearch payments

9. A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

   Completed · Phase 3 · Respiratory Syncytial Virus

   NCT06067230 · ModernaTX, Inc. · 33 U.S. investigators

   $4.4Mresearch payments

10. A Multidisciplinary "Integrated Management Team to Improve Maternal-Child Outcomes (IMPROVE)" Intervention to Improve Maternal and Child Outcomes in Lesotho

    Completed · Not applicable · Human Immunodeficiency Virus

    NCT04598958 · Philips North America LLC · 5 U.S. investigators

    $4.4Mresearch payments

11. Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

    Completed · Phase 3 · Contraception

    NCT04756037 · Sumitomo Pharma America, Inc. · 122 U.S. investigators

    $4.4Mresearch payments

12. Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

    Recruiting · Phase 1, Phase 2 · Acne

    NCT06316297 · Sanofi Pasteur Inc. · 56 U.S. investigators

    $4.4Mresearch payments

13. A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

    Active, not recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT06637501 · Beone Medicines USA, Inc. · 14 U.S. investigators

    $4.4Mresearch payments

14. ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

    Enrolling by invitation · Phase 3 · Alzheimer's Disease Psychosis

    NCT06194799 · Acadia Pharmaceuticals Inc · 20 U.S. investigators

    $4.3Mresearch payments

15. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Recruiting · Phase 1 · Hepatocellular Carcinoma

    NCT06084481 · AbbVie Inc. · 24 U.S. investigators

    $4.3Mresearch payments

16. A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

    Active, not recruiting · Phase 1, Phase 2 · CD19+ Acute Leukemia

    NCT02028455 · E.r. Squibb & Sons, L.l.c. · 14 U.S. investigators

    $4.3Mresearch payments

17. Innovative Automated Insulin Delivery System for Type 2 Diabetes

    Completed · Not applicable · Type 2 Diabetes

    NCT06853990 · Sequel Med Tech, LLC · 30 U.S. investigators

    $4.2Mresearch payments

18. A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

    Recruiting · Phase 2 · Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    NCT05519475 · Regeneron Pharmaceuticals, Inc. · 54 U.S. investigators

    $4.2Mresearch payments

19. Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

    Completed · Phase 2, Phase 3 · Diabetic Macular Edema

    NCT04429503 · Regeneron Pharmaceuticals, Inc. · 86 U.S. investigators

    $4.2Mresearch payments

20. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

    Recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT06428019 · AbbVie Inc. · 30 U.S. investigators

    $4.2Mresearch payments

21. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    Recruiting · Phase 1, Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    NCT03972657 · Regeneron Pharmaceuticals, Inc. · 20 U.S. investigators

    $4.2Mresearch payments

22. A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

    Recruiting · Phase 1, Phase 2 · Solid Tumor

    NCT05584670 · Sanofi US Services Inc. · 7 U.S. investigators

    $4.1Mresearch payments

23. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Recruiting · Phase 1 · Multiple Myeloma

    NCT05137054 · Regeneron Pharmaceuticals, Inc. · 14 U.S. investigators

    $4.1Mresearch payments

24. A Study of LY3841136 in Overweight and Obese Participants

    Completed · Phase 1 · Obesity

    NCT06345066 · Eli Lilly and Company · 3 U.S. investigators

    $4.1Mresearch payments

25. Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

    Terminated · Phase 3 · Post-COVID Postural Orthostatic Tachycardia Syndrome

    NCT06524739 · Csl Behring · 25 U.S. investigators

    $4.1Mresearch payments

26. Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

    Active, not recruiting · Phase 2, Phase 3 · Dermatitis Atopic

    NCT05492578 · Sanofi US Services Inc. · 74 U.S. investigators

    $4.0Mresearch payments

27. A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

    Recruiting · Phase 3 · Age-related Macular Degeneration (AMD)

    NCT06541704 · Regeneron Pharmaceuticals, Inc. · 124 U.S. investigators

    $4.0Mresearch payments

28. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    Recruiting · Phase 2 · Obesity

    NCT06143956 · Eli Lilly and Company · 53 U.S. investigators

    $4.0Mresearch payments

29. A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    Completed · Phase 1 · Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    NCT05395481 · Eli Lilly and Company · 15 U.S. investigators

    $4.0Mresearch payments

30. A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

    Completed · Phase 3 · Dermatitis Atopic

    NCT06181435 · Sanofi US Services Inc. · 47 U.S. investigators

    $4.0Mresearch payments

31. A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

    Recruiting · Phase 1, Phase 2 · Metastatic Castration-resistant Prostate Cancer

    NCT05125016 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

    $3.9Mresearch payments

32. A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

    Active, not recruiting · Phase 3 · Dermatitis Atopic

    NCT06241118 · Sanofi US Services Inc. · 35 U.S. investigators

    $3.9Mresearch payments

33. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

    Active, not recruiting · Phase 1 · Non-Small Cell Lung Cancer

    NCT05029882 · AbbVie Inc. · 27 U.S. investigators

    $3.9Mresearch payments

34. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Recruiting · Phase 1 · Non-Small Cell Lung Cancer

    NCT05005403 · AbbVie Inc. · 17 U.S. investigators

    $3.9Mresearch payments

35. A First-In-Human Study of LY3839840 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06153355 · Eli Lilly and Company · 2 U.S. investigators

    $3.9Mresearch payments

36. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

    Completed · Phase 3 · Obesity

    NCT05882045 · Eli Lilly and Company · 56 U.S. investigators

    $3.9Mresearch payments

37. An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

    Completed · Phase 2 · Multiple Myeloma

    NCT03601078 · Celgene Corporation · 18 U.S. investigators

    $3.9Mresearch payments

38. A Study of Remternetug (LY3372993) in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT07056309 · Eli Lilly and Company · 3 U.S. investigators

    $3.8Mresearch payments

39. A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

    Completed · Phase 2 · Narcolepsy Type 2

    NCT06555783 · Alkermes, Inc. · 39 U.S. investigators

    $3.8Mresearch payments

40. FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

    Recruiting · Phase 1 · Urinary Bladder Neoplasms

    NCT05614739 · Eli Lilly and Company · 31 U.S. investigators

    $3.8Mresearch payments

41. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

    Recruiting · Phase 1, Phase 2 · Relapsed/Refractory Multiple Myeloma

    NCT04973605 · Beone Medicines Ltd. · 17 U.S. investigators

    $3.8Mresearch payments

42. Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

    Completed · Phase 2 · Celiac Disease

    NCT04530123 · Takeda Pharmaceuticals U.S.A., Inc. · 35 U.S. investigators

    $3.8Mresearch payments

43. A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

    Terminated · Phase 3 · Blepharitis

    NCT06400511 · Oyster Point Pharma, Inc. · 26 U.S. investigators

    $3.7Mresearch payments

44. Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

    Active, not recruiting · Phase 2 · Prolymphocytic Leukemia

    NCT02007044 · AbbVie Inc. · 1 U.S. investigator

    $3.7Mresearch payments

45. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    Recruiting · Phase 1, Phase 2 · B-cell Malignancy

    NCT05006716 · Beone Medicines USA, Inc. · 34 U.S. investigators

    $3.7Mresearch payments

46. A Study of LY3971297 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06148272 · Eli Lilly and Company · 2 U.S. investigators

    $3.6Mresearch payments

47. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

    Recruiting · Phase 3 · Mantle Cell Lymphoma

    NCT06742996 · Beone Medicines Ltd. · 39 U.S. investigators

    $3.6Mresearch payments

48. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

    Completed · Phase 1 · Obesity

    NCT06824051 · Eli Lilly and Company · 4 U.S. investigators

    $3.6Mresearch payments

49. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    Recruiting · Phase 1, Phase 2 · Recurrent or Metastatic Solid Tumors

    NCT06330064 · Daiichi Sankyo Inc. · 18 U.S. investigators

    $3.5Mresearch payments

50. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

    Completed · Phase 1 · Epstein-Barr Virus Infection

    NCT05831111 · ModernaTX, Inc. · 39 U.S. investigators

    $3.5Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.